BRIXADI (buprenorphine extended-release): Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See NDA 210136's history or Braeburn Pharmaceuticals's company page.
On Jan 19, 2018, FDA declined to approve BRIXADI (buprenorphine extended-release) (NDA 210136) from Braeburn Pharmaceuticals Inc. in its present form, citing clinical/statistical, nonclinical, product quality. The application was later approved.
- Letter date: Jan 19, 2018
- Application: NDA 210136
- Since then: Approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDA1. There are insufficient clinical data | Information needed to resolve deficiency Provide additional data ©® or withdraw it from the application. 2. The submitted clinical datasets were found to include a number of discrepancies and. errors, which you have de...… openFDA did not return the full text just now. Open it in the letter search.
Other Letters on This Application
- BRIXADI (buprenorphine)Dec 15, 2021 · NDA 210136 · later approved
- BRIXADI (buprenorphine)Dec 1, 2020 · NDA 210136 · later approved
Record
- Company
- Braeburn Pharmaceuticals Inc.
- Application
- NDA 210136
- Status in openFDA
- Approved
- Review division
- Office of Drug Evaluation II
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters